Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Lung Cancer

  Free Subscription


12.04.2021

1 Am J Clin Oncol
1 Am J Respir Crit Care Med
4 Ann Thorac Surg
6 Anticancer Res
6 BMC Cancer
1 Br J Cancer
1 Cancer
1 Cancer Chemother Pharmacol
1 Cancer Epidemiol Biomarkers Prev
4 Cancer Sci
1 Clin Cancer Res
8 Clin Lung Cancer
1 Clin Nucl Med
3 Eur J Cancer
3 Int J Cancer
5 Int J Radiat Oncol Biol Phys
1 J Clin Oncol
2 J Comput Assist Tomogr
1 J Immunol
1 J Natl Cancer Inst
3 J Thorac Cardiovasc Surg
2 J Thorac Oncol
1 JAMA Oncol
19 Lung Cancer
3 Mol Cancer Ther
1 Nat Rev Cancer
1 Oncologist
1 PLoS One
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Clin Oncol

  1. PARSAI S, Sedor G, Smile TD, Scott J, et al
    Multiple Site SBRT in Pediatric, Adolescent, and Young Adult Patients With Recurrent and/or Metastatic Sarcoma.
    Am J Clin Oncol. 2021;44:126-130.
    PubMed         Abstract available


    Am J Respir Crit Care Med

  2. GOULD MK, Huang BZ, Tammemagi MC, Kinar Y, et al
    Machine Learning for Early Lung Cancer Identification Using Routine Clinical and Laboratory Data.
    Am J Respir Crit Care Med. 2021 Apr 6. doi: 10.1164/rccm.202007-2791.
    PubMed         Abstract available


    Ann Thorac Surg

  3. DENG H, Cheng B, He J
    Family History Associates With Micropapillary Pattern in Lung Adenocarcinoma
    Ann Thorac Surg. 2021;111:1412-1413.
    PubMed        

  4. NAKAZAWA S, Hanawa R, Nagashima T, Shimizu K, et al
    Segmentectomy Guided by 3D Images Reconstructed from Non-enhanced Computed Tomography Data.
    Ann Thorac Surg. 2020 Oct 31. pii: S0003-4975(20)31829.
    PubMed         Abstract available

  5. LIU HY, Hsu HH, Tsai TM, Chiang XH, et al
    Nonintubated Versus Intubated Uniportal Thoracoscopic Segmentectomy for Lung Tumors.
    Ann Thorac Surg. 2021;111:1182-1189.
    PubMed         Abstract available

  6. SANZ-SANTOS J, Martinez-Palau M, Jaen A, Rami-Porta R, et al
    Geometrical Measurement of Central Tumor Location in cT1N0M0 NSCLC Predicts N1 but Not N2 Upstaging.
    Ann Thorac Surg. 2021;111:1190-1197.
    PubMed         Abstract available


    Anticancer Res

  7. KINOSHITA F, Yamashita T, Oku Y, Kosai K, et al
    Prognostic Impact of Albumin-bilirubin (ALBI) Grade on Non-small Lung Cell Carcinoma: A Propensity-score Matched Analysis.
    Anticancer Res. 2021;41:1621-1628.
    PubMed         Abstract available

  8. FUKUDA N, Toda K, Ohmoto A, Wang X, et al
    Baseline Tumour Size as a Prognostic Factor for Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib.
    Anticancer Res. 2021;41:1683-1691.
    PubMed         Abstract available

  9. SVATON M, Bratova M, Fischer O, Krejci J, et al
    Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study.
    Anticancer Res. 2021;41:2059-2065.
    PubMed         Abstract available

  10. TOZUKA T, Yanagitani N, Yoshida H, Manabe R, et al
    Impact of Renin-angiotensin System Inhibitors on the Efficacy of Anti-PD-1/PD-L1 Antibodies in NSCLC Patients.
    Anticancer Res. 2021;41:2093-2100.
    PubMed         Abstract available

  11. TSUKIOKA T, Izumi N, Komatsu H, Inoue H, et al
    Tumor Size and N2 Lymph Node Metastasis Are Significant Risk Factors for Early Recurrence in Completely Resected Centrally Located Primary Lung Cancer Patients.
    Anticancer Res. 2021;41:2165-2169.
    PubMed         Abstract available

  12. MON MM, Srisomsap C, Chokchaichamnankit D, Watcharatanyatip K, et al
    Serum Proteomic Profiling Reveals Differentially Expressed IGHG3 and A1AG1 as Potential Predictors of Chemotherapeutic Response in Advanced Non-small Cell Lung Cancer.
    Anticancer Res. 2021;41:1871-1882.
    PubMed         Abstract available


    BMC Cancer

  13. BOZORGMEHR F, Chung I, Christopoulos P, Krisam J, et al
    Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial.
    BMC Cancer. 2020;20:806.
    PubMed         Abstract available

  14. DUAN H, Liang L, Xie S, Wang C, et al
    The impact of order with radiation therapy in stage IIIA pathologic N2 NSCLC patients: a population-based study.
    BMC Cancer. 2020;20:809.
    PubMed         Abstract available

  15. BU X, Liu J, Wei L, Wang X, et al
    Epidemiological features and survival outcomes in patients with malignant pulmonary blastoma: a US population-based analysis.
    BMC Cancer. 2020;20:811.
    PubMed         Abstract available

  16. HOSOYA K, Fujimoto D, Morimoto T, Kumagai T, et al
    Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study.
    BMC Cancer. 2021;21:346.
    PubMed         Abstract available

  17. HUANG YS, Chen JL, Chen HM, Yeh LH, et al
    Assessing tumor angiogenesis using dynamic contrast-enhanced integrated magnetic resonance-positron emission tomography in patients with non-small-cell lung cancer.
    BMC Cancer. 2021;21:348.
    PubMed         Abstract available

  18. BADE BC, Gan G, Li F, Lu L, et al
    "Randomized trial of physical activity on quality of life and lung cancer biomarkers in patients with advanced stage lung cancer: a pilot study".
    BMC Cancer. 2021;21:352.
    PubMed         Abstract available


    Br J Cancer

  19. AMERATUNGA M, Brana I, Bono P, Postel-Vinay S, et al
    First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.
    Br J Cancer. 2020;123:1730-1736.
    PubMed         Abstract available


    Cancer

  20. PARK S, Olsen S, Ku BM, Lee MS, et al
    High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean lung liquid versus invasive biopsy program.
    Cancer. 2021 Apr 7. doi: 10.1002/cncr.33571.
    PubMed         Abstract available


    Cancer Chemother Pharmacol

  21. LIU M, Yan Q, Peng B, Cai Y, et al
    Use of cucurbitacins for lung cancer research and therapy.
    Cancer Chemother Pharmacol. 2021 Apr 6. pii: 10.1007/s00280-021-04265.
    PubMed         Abstract available


    Cancer Epidemiol Biomarkers Prev

  22. WILUNDA C, Sawada N, Yamaji T, Iwasaki M, et al
    Reproductive factors and lung cancer risk among never-smoking Japanese women with 21 years of follow-up: a cohort study.
    Cancer Epidemiol Biomarkers Prev. 2021 Apr 7. pii: 1055-9965.EPI-20-1399.
    PubMed         Abstract available


    Cancer Sci

  23. ISOMURA H, Taguchi A, Kajino T, Asai N, et al
    Conditional Ror1 knockout reveals crucial involvement in lung adenocarcinoma development and identifies novel HIF-1alpha regulator.
    Cancer Sci. 2021;112:1614-1623.
    PubMed         Abstract available

  24. NISHIO M, Saito H, Goto K, Watanabe S, et al
    IMpower132: Atezolizumab plus platinum-based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients.
    Cancer Sci. 2021;112:1534-1544.
    PubMed         Abstract available

  25. SETO T, Ohashi K, Sugawara S, Nishio M, et al
    Capmatinib in Japanese patients with MET exon 14 skipping-mutated or MET-amplified advanced NSCLC: GEOMETRY mono-1 study.
    Cancer Sci. 2021;112:1556-1566.
    PubMed         Abstract available

  26. FUJIMOTO M, Kamiyama M, Fuse K, Ryuno H, et al
    ASK1 suppresses NK cell-mediated intravascular tumor cell clearance in lung metastasis.
    Cancer Sci. 2021;112:1633-1643.
    PubMed         Abstract available


    Clin Cancer Res

  27. SHAFIQUE M, Fisher TL, Evans EE, Leonard JE, et al
    A Phase 1b/2 Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2021 Apr 5. pii: 1078-0432.CCR-20-4792.
    PubMed         Abstract available


    Clin Lung Cancer

  28. GELSOMINO F, Di Federico A, Filippini DM, Dall'Olio FG, et al
    Overcoming Primary Resistance to PD-1 Inhibitor With Anti-PD-L1 Agent in Squamous-Cell NSCLC: Case Report.
    Clin Lung Cancer. 2020;21:e45-e48.
    PubMed        

  29. KINSLOW CJ, May MS, Saqi A, Shu CA, et al
    Large-Cell Neuroendocrine Carcinoma of the Lung: A Population-Based Study.
    Clin Lung Cancer. 2020;21:e99-e113.
    PubMed         Abstract available

  30. ERSEK JL, Symanowski JT, Han Y, Howard A, et al
    Pulmonary Carcinosarcoma: A Surveillance, Epidemiology, and End Results (SEER) Analysis.
    Clin Lung Cancer. 2020;21:160-170.
    PubMed         Abstract available

  31. TANNER NT, Brasher PB, Jett J, Silvestri GA, et al
    Effect of a Rule-in Biomarker Test on Pulmonary Nodule Management: A Survey of Pulmonologists and Thoracic Surgeons.
    Clin Lung Cancer. 2020;21:e89-e98.
    PubMed         Abstract available

  32. BARBOSA MVR, Cordeiro de Lima VC, Formiga MN, Andrade de Paula CA, et al
    High Prevalence of EGFR Mutations in Lung Adenocarcinomas From Brazilian Patients Harboring the TP53 p.R337H Variant.
    Clin Lung Cancer. 2020;21:e37-e44.
    PubMed        

  33. MATSUBARA T, Uchi H, Haratake N, Takamori S, et al
    Acute Generalized Exanthematous Pustulosis Caused by the Combination of Pembrolizumab Plus Chemotherapy in a Patient With Squamous-Cell Carcinoma.
    Clin Lung Cancer. 2020;21:e54-e56.
    PubMed        

  34. MAZZASCHI G, Bordi P, Fioretzaki R, Gnetti L, et al
    Nivolumab-Induced Guillain-Barre Syndrome Coupled With Remarkable Disease Response in a Case of Heavily Pretreated Lung Adenocarcinoma.
    Clin Lung Cancer. 2020;21:e65-e73.
    PubMed        

  35. ZHANG Y, Yu M, Yuan M, Chen R, et al
    Identification of a Novel RBPMS-ROS1 Fusion in an Adolescent Patient With Microsatellite-instable Advanced Lung Adenocarcinoma Sensitive to Crizotinib: A Case Report.
    Clin Lung Cancer. 2020;21:e78-e83.
    PubMed        


    Clin Nucl Med

  36. SHARMA P
    Adenocarcinoma of the Lung With Initial Presentation as Painful Testicular Metastasis: 18F-FDG PET/CT Findings in an Unusual Case.
    Clin Nucl Med. 2020 Sep 15. doi: 10.1097/RLU.0000000000003292.
    PubMed         Abstract available


    Eur J Cancer

  37. PROVENCIO M, Serna-Blasco R, Franco F, Calvo V, et al
    Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment.
    Eur J Cancer. 2021;149:61-72.
    PubMed         Abstract available

  38. TANAKA K, Asahina H, Kishimoto J, Miyata Y, et al
    Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial.
    Eur J Cancer. 2021;149:14-22.
    PubMed         Abstract available

  39. OCHI N, Ichihara E, Takigawa N, Harada D, et al
    The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
    Eur J Cancer. 2021;149:73-81.
    PubMed         Abstract available


    Int J Cancer

  40. KATO M, Onoyama I, Yoshida S, Cui L, et al
    Dual specificity phosphatase 6 plays a critical role in the maintenance of a cancer stem-like cell phenotype in human endometrial cancer.
    Int J Cancer. 2020 Mar 11. doi: 10.1002/ijc.32965.
    PubMed         Abstract available

  41. GRAU N, Scherer SD, Rothley M, Rosswag S, et al
    Spatiotemporally controlled induction of gene expression in vivo allows tracking the fate of tumor cells that traffic through the lymphatics.
    Int J Cancer. 2020;147:1190-1198.
    PubMed         Abstract available

  42. CAI L, Chen Y, Tong X, Wu X, et al
    The genomic landscape of young and old lung cancer patients highlights age-dependent mutation frequencies and clinical actionability in young patients.
    Int J Cancer. 2021 Apr 2. doi: 10.1002/ijc.33583.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  43. TOMA-DASU I, Moiseenko V, Purdie TG, Carlson DJ, et al
    Recent Developments in the Prediction of Clinical Outcomes Data in Radiation Oncology.
    Int J Radiat Oncol Biol Phys. 2020;108:513-517.
    PubMed        

  44. GUTIONTOV SI, Pitroda SP, Weichselbaum RR
    Oligometastasis: Past, Present, Future.
    Int J Radiat Oncol Biol Phys. 2020;108:530-538.
    PubMed         Abstract available

  45. MIRSCH J, Hintz L, Maier A, Fournier C, et al
    An Assessment of Radiation Doses From Radon Exposures Using a Mouse Model System.
    Int J Radiat Oncol Biol Phys. 2020;108:770-778.
    PubMed         Abstract available

  46. TIAN S, Switchenko JM, Buchwald ZS, Patel PR, et al
    Lung Stereotactic Body Radiation Therapy and Concurrent Immunotherapy: A Multicenter Safety and Toxicity Analysis.
    Int J Radiat Oncol Biol Phys. 2020;108:304-313.
    PubMed         Abstract available

  47. YIN L, Xue J, Li R, Zhou L, et al
    Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients With Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2020;108:212-224.
    PubMed         Abstract available


    J Clin Oncol

  48. BEKELMAN JE, Gupta A, Fishman E, Debono D, et al
    Association Between a National Insurer's Pay-for-Performance Program for Oncology and Changes in Prescribing of Evidence-Based Cancer Drugs and Spending.
    J Clin Oncol. 2020;38:4055-4063.
    PubMed         Abstract available


    J Comput Assist Tomogr

  49. YEN A, Pfeffer Y, Blumenfeld A, Balcombe JN, et al
    Use of a Dual Artificial Intelligence Platform to Detect Unreported Lung Nodules.
    J Comput Assist Tomogr. 2021;45:318-322.
    PubMed         Abstract available

  50. CHANG AI, Kim TS, Han J, Kim TJ, et al
    NUT Midline Carcinoma of the Lung: Computed Tomography Findings in 10 Patients.
    J Comput Assist Tomogr. 2021;45:330-336.
    PubMed         Abstract available


    J Immunol

  51. KOHNO M, Murakami J, Wu L, Chan ML, et al
    Foxp3(+) Regulatory T Cell Depletion after Nonablative Oligofractionated Irradiation Boosts the Abscopal Effects in Murine Malignant Mesothelioma.
    J Immunol. 2020;205:2519-2531.
    PubMed         Abstract available


    J Natl Cancer Inst

  52. MITCHELL AP, Bach PB
    Use of Positron Emission Tomography Imaging: Another Nonbiological Source of Racial Disparities in US Cancer Care.
    J Natl Cancer Inst. 2020;112:1177-1178.
    PubMed        


    J Thorac Cardiovasc Surg

  53. HOD T, Freedberg KJ, Motwani SS, Chen M, et al
    Acute kidney injury after cytoreductive surgery and hyperthermic intraoperative cisplatin chemotherapy for malignant pleural mesothelioma.
    J Thorac Cardiovasc Surg. 2021;161:1510-1518.
    PubMed         Abstract available

  54. DONAHOE LL, Nason GJ, Bedard PL, Hansen AR, et al
    Pathologic concordance of resected metastatic nonseminomatous germ cell tumors in the chest.
    J Thorac Cardiovasc Surg. 2021;161:856-868.
    PubMed         Abstract available

  55. SHEMANSKI KA, Farias A, Lieu D, Kim AW, et al
    Understanding thoracic surgeons' perceptions of administrative database analyses and guidelines in clinical decision-making.
    J Thorac Cardiovasc Surg. 2021;161:807-816.
    PubMed         Abstract available


    J Thorac Oncol

  56. JOHNSON ML, Zvirbule Z, Laktionov K, Helland A, et al
    Rovalpituzumab Tesirine as a Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From the Phase 3 MERU Study.
    J Thorac Oncol. 2021 Apr 3. pii: S1556-0864(21)02067.
    PubMed         Abstract available

  57. SCARFONE G, Fumagalli M, Imbimbo M, Ceruti T, et al
    First Case Report of Pregnancy on Alectinib in a Woman With Metastatic ALK-Rearranged Lung Cancer: A Case Report.
    J Thorac Oncol. 2021 Mar 29. pii: S1556-0864(21)01705.
    PubMed         Abstract available


    JAMA Oncol

  58. KAMRAN SC, Yeap BY, Ulysse CA, Cronin C, et al
    Assessment of a Contralateral Esophagus-Sparing Technique in Locally Advanced Lung Cancer Treated With High-Dose Chemoradiation: A Phase 1 Nonrandomized Clinical Trial.
    JAMA Oncol. 2021 Apr 8. pii: 2778095. doi: 10.1001/jamaoncol.2021.0281.
    PubMed         Abstract available


    Lung Cancer

  59. MORENO V, Garrido P, Papadopoulos KP, De Miguel Luken MJ, et al
    Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort.
    Lung Cancer. 2021;155:151-155.
    PubMed         Abstract available

  60. ZHAO J, Lin G, Zhuo M, Fan Z, et al
    Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib.
    Lung Cancer. 2020;141:114-118.
    PubMed         Abstract available

  61. PARK K, Chang GC, Curigliano G, Lim WT, et al
    Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation.
    Lung Cancer. 2021;155:127-135.
    PubMed         Abstract available

  62. WU H, Dong S, Li X, Shi L, et al
    Clinical utility of dual-energy CT used as an add-on to 18F FDG PET/CT in the preoperative staging of resectable NSCLC with suspected single osteolytic metastases.
    Lung Cancer. 2020;140:80-86.
    PubMed         Abstract available

  63. BISSONNETTE JP, Sun A, Grills IS, Almahariq MF, et al
    Non-small cell lung cancer stage migration as a function of wait times from diagnostic imaging: A pooled analysis from five international centres.
    Lung Cancer. 2021;155:136-143.
    PubMed         Abstract available

  64. REALE ML, Chiari R, Tiseo M, Vitiello F, et al
    Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients.
    Lung Cancer. 2020;140:71-79.
    PubMed         Abstract available

  65. BALDINI E, Lunghi A, Cortesi E, Turci D, et al
    Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program.
    Lung Cancer. 2020;140:59-64.
    PubMed         Abstract available

  66. GIBERT J, Clave S, Hardy-Werbin M, Taus A, et al
    Concomitant genomic alterations in KRAS mutant advanced lung adenocarcinoma.
    Lung Cancer. 2020;140:42-45.
    PubMed         Abstract available

  67. SANDS JM, Nguyen T, Shivdasani P, Sacher AG, et al
    Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas.
    Lung Cancer. 2020;140:35-41.
    PubMed         Abstract available

  68. EDAHIRO R, Shiroyama T, Hijiki S, Nojima S, et al
    Severe myocarditis with slight lymphocytic infiltration after nivolumab treatment.
    Lung Cancer. 2020;140:116-117.
    PubMed        

  69. SHOJI S, Watanabe S, Takamura K, Umezu H, et al
    First-line osimertinib treatment in patients with lung squamous cell carcinoma harboring active epidermal growth factor receptor mutations.
    Lung Cancer. 2020;140:113-115.
    PubMed        

  70. LAM WS, Creaney J, Chen FK, Chin WL, et al
    A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma.
    Lung Cancer. 2020;140:87-92.
    PubMed         Abstract available

  71. WANG F, Qin J, Xie F, Wu Q, et al
    Transformation of EML4-ALK fusion-positive adenocarcinoma into squamous cell carcinoma in association with acquired resistance to crizotinib.
    Lung Cancer. 2020;140:118-120.
    PubMed        

  72. FURUKAWA R, Inoue H, Yoneshima Y, Tsutsumi H, et al
    Cytotoxic chemotherapeutic agents and the EGFR-TKI osimertinib induce calreticulin exposure in non-small cell lung cancer.
    Lung Cancer. 2021;155:144-150.
    PubMed         Abstract available

  73. LI C, Shen Y, Hu F, Chu T, et al
    Micropapillary pattern is associated with the development of brain metastases and the reduction of survival time in EGFR-mutation lung adenocarcinoma patients with surgery.
    Lung Cancer. 2020;141:72-77.
    PubMed         Abstract available

  74. GOSNEY JR, Boothman AM, Ratcliffe M, Kerr KM, et al
    Cytology for PD-L1 testing: A systematic review.
    Lung Cancer. 2020;141:101-106.
    PubMed         Abstract available

  75. ITO M, Miyata Y, Tsutani Y, Ito H, et al
    Positive EGFR mutation status is a risk of recurrence in pN0-1 lung adenocarcinoma when combined with pathological stage and histological subtype: A retrospective multi-center analysis.
    Lung Cancer. 2020;141:107-113.
    PubMed         Abstract available

  76. EPAILLARD N, Benitez JC, Gorria T, Fabre E, et al
    Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie study.
    Lung Cancer. 2021;155:114-119.
    PubMed         Abstract available

  77. TASAKA Y, Honda T, Nishiyama N, Tsutsui T, et al
    Non-inferior clinical outcomes of immune checkpoint inhibitors in non-small cell lung cancer patients with interstitial lung disease.
    Lung Cancer. 2021;155:120-126.
    PubMed         Abstract available


    Mol Cancer Ther

  78. YAMASHITA D, Minata M, Ibrahim AN, Yamaguchi S, et al
    Identification of ALDH1A3 as a Viable Therapeutic Target in Breast Cancer Metastasis-Initiating Cells.
    Mol Cancer Ther. 2020;19:1134-1147.
    PubMed         Abstract available

  79. KOTANIDES H, Sattler RM, Lebron MB, Carpenito C, et al
    Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity.
    Mol Cancer Ther. 2020;19:988-998.
    PubMed         Abstract available

  80. ZENKE FT, Zimmermann A, Sirrenberg C, Dahmen H, et al
    Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models.
    Mol Cancer Ther. 2020;19:1091-1101.
    PubMed         Abstract available


    Nat Rev Cancer

  81. SETON-ROGERS S
    A driver gene hiding in plain sight.
    Nat Rev Cancer. 2021;21:213.
    PubMed        


    Oncologist

  82. BERNICKER EH, Xiao Y, Abraham A, Yang B, et al
    Adherence to NCCN ALK testing guidelines for patients with advanced non-small cell lung cancer in US Community Medical Centers.
    Oncologist. 2021 Apr 6. doi: 10.1002/onco.13779.
    PubMed         Abstract available


    PLoS One

  83. HUH DA, Kang MS, Lee J, Choi JY, et al
    Occupational and environmental asbestos exposure and the risk of lung cancer in Korea: A case-control study in South Chungcheong Province of Korea.
    PLoS One. 2021;16:e0249790.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  84. YANG L, Yan X, Chen J, Zhan Q, et al
    Hexokinase 2 discerns a novel circulating tumor cell population associated with poor prognosis in lung cancer patients.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: